Therapeutics targeting IL-13 for the treatment of pulmonary inflammation and airway remodeling.

Abstract

Targeting the IL-13 pathway appears to be a viable approach to ameliorate pulmonary inflammation and remodeling. Support for this hypothesis comes from preclinical and preliminary clinical data. Diverse approaches have been used to target the IL-13 pathway, including neutralizing antibodies specific for IL-13, targeting IL-13 receptors using antibodies or chimeric proteins, and therapeutics that target the downstream signaling molecules that are activated upon binding of the IL-13 receptor to its ligand. This review summarizes the progress made in the development of therapeutics targeting the IL-13 pathway for treating diseases associated with inflammation and remodeling of the lung.

• Authors: Kate Blease
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 9 Issue 11 Pg. 1180-4 (Nov 2008) ISSN: 1472-4472 [Print] England
• PMID: 18951297 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal
• Interleukin-13
• Receptors, Interleukin-13
• STAT6 Transcription Factor
• Interleukin-4

Topics

• Animals
• Antibodies, Monoclonal (therapeutic use)
• Asthma (drug therapy)
• Bronchial Hyperreactivity (drug therapy)
• Humans
• Interleukin-13 (antagonists & inhibitors)
• Interleukin-4 (antagonists & inhibitors)
• Pulmonary Fibrosis (drug therapy)
• Receptors, Interleukin-13 (antagonists & inhibitors)
• STAT6 Transcription Factor (antagonists & inhibitors)